SEC Form SC 13G/A filed by Checkmate Pharmaceuticals, Inc. (Amendment)

$CMPI
Specialty Chemicals
Consumer Durables
Get the next $CMPI alert in real time by email
SC 13G/A 1 d181579dsc13ga.htm SC 13G/A SC 13G/A
CUSIP No. 162818108   13G   Page 1  of 8

 

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

 

 

Checkmate Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

162818108

(CUSIP Number)

May 7, 2021

(Date of Event Which Requires Filing of This Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☒ Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


CUSIP No. 22026V105   13G   Page 2 of 8

 

  1.    

  NAME OF REPORTING PERSONS / I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

 

  CLOUGH CAPITAL PARTNERS L.P.

  2.  

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

  (A)  ☐        (B)  ☐

 

  3.  

  SEC USE ONLY

 

  4.  

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  DELAWARE

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH:

   5.     

  SOLE VOTING POWER

 

  0

   6.   

  SHARED VOTING POWER

 

  1,552,326 (see Item 4)

   7.   

  SOLE DISPOSITIVE POWER

 

  0

   8.   

  SHARED DISPOSITIVE POWER

 

  1,552,326 (see Item 4)

  9.    

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  1,552,326 (see Item 4)

10  

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*    ☐

 

11.  

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

  7.18% (see Item 4)

12.  

  TYPE OF REPORTING PERSON

 

  IA – Investment Adviser


CUSIP No. 22026V105   13G   Page 3 of 8

 

  1.    

  NAME OF REPORTING PERSONS / I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

 

  CLOUGH CAPITAL PARTNERS LLC

  2.  

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

  (A)  ☐        (B)  ☐

 

  3.  

  SEC USE ONLY

 

  4.  

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  DELAWARE

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH:

   5.     

  SOLE VOTING POWER

 

  0

   6.   

  SHARED VOTING POWER

 

  1,552,326 (see Item 4)

   7.   

  SOLE DISPOSITIVE POWER

 

  0

   8.   

  SHARED DISPOSITIVE POWER

 

  1,552,326 (see Item 4)

  9.    

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  1,552,326 (see Item 4)

10  

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*    ☐

 

11.  

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

  7.18% (see Item 4)

12.  

  TYPE OF REPORTING PERSON

 

  HC – Parent Holding Company/Control Person


CUSIP No. 22026V105   13G   Page 4 of 8

 

  1.    

  NAME OF REPORTING PERSONS / I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

 

  CHARLES I. CLOUGH, JR.

  2.  

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

  (A)  ☐        (B)  ☐

 

  3.  

  SEC USE ONLY

 

  4.  

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  UNITED STATES

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH:

   5.     

  SOLE VOTING POWER

 

  0

   6.   

  SHARED VOTING POWER

 

  1,552,326 (see Item 4)

   7.   

  SOLE DISPOSITIVE POWER

 

  0

   8.   

  SHARED DISPOSITIVE POWER

 

  1,552,326 (see Item 4)

  9.    

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  1,552,326 (see Item 4)

10  

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*    ☐

 

11.  

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

  7.18% (see Item 4)

12.  

  TYPE OF REPORTING PERSON

 

  HC – Parent Holding Company/Control Person


CUSIP No. 22026V105   13G   Page 5 of 8

 

ITEM 1.

 

(a) Name of Issuer: Checkmate Pharmaceuticals, Inc.
(b) Address of Issuer’s Principal Executive Offices:
 

245 Main Street

 

2nd Floor

 

Cambridge MA, 02142

ITEM 2.

 

(a) and (c)   Name and Domicile/Citizenship of Persons Filing:
  (i) Clough Capital Partners L.P., a Delaware limited partnership.
  (ii) Clough Capital Partners LLC, a Delaware limited liability company.
  (iii) Charles I. Clough, Jr., a United States citizen.
(b)   Each of the Reporting Persons has a business address of:
 

53 State Street, 27th Floor, Boston, MA 02109.

(d)   Title of Class of Securities: Common Stock, par value $0.01 per share.
(e)   CUSIP Number: 162818108

 

ITEM 3.

IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), OR 13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

 

(a)       Broker or Dealer registered under Section 15 of the Act
(b)       Bank as defined in section 3(a)(6) of the Act
(c)       Insurance Company as defined in section 3(a)(19) of the Act
(d)       Investment Company registered under section 8 of the Investment Company Act of 1940
(e)       Investment Adviser registered under section 203 of the Investment Advisers Act or under the laws of any State
(f)       Employee Benefit Plan, Pension fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund; see Section 240.13d-1(b)(1)(ii)(F)
(g)       A Parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G) (Note: See Item 7)
(h)       A Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act
(i)       A Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940
(j)       Group, in accordance with Section 240.13d-1(b)(1)(ii)(J)


CUSIP No. 22026V105   13G   Page 6 of 8

 

ITEM 4.

OWNERSHIP

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

     

(a)   Amount Beneficially Owned: 1,552,326*

     

(b)   Percent of Class: 7.18%*

     

(c)   Number of shares as to which such person has:

     

(i) sole power to vote or to direct the vote: 0

     

(ii)  shared power to vote or to direct the vote: 1,552,326*

     

(iii)  sole power to dispose or to direct the disposition of: 0

     

(iv) shared power to dispose or to direct the disposition of: 1,552,326*

 

*

The shares reported above include shares beneficially owned by investment companies, pooled investment vehicles and other accounts for which Clough Capital Partners L.P. serves as investment adviser. Such shares may be deemed beneficially owned by (a) Clough Capital Partners L.P., (b) Clough Capital Partners LLC, the general partner of Clough Capital Partners L.P., and (c) Mr. Clough, the managing member of Clough Capital Partners LLC. Each such reporting person disclaims beneficial ownership of such shares except to the extent of its respective pecuniary interest therein.

The share holding and percent of class data set forth above is reported as of the date of the filing of this statement on Schedule 13G.

 

ITEM 5.

OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☐.

 

ITEM 6

OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

Not Applicable.

 

ITEM 7.

IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

See Item 4


CUSIP No. 22026V105   13G   Page 7 of 8

 

ITEM 8.

IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

Not Applicable.

 

ITEM 9.

NOTICE OF DISSOLUTION OF GROUP

Not Applicable.

 

ITEM 10.

CERTIFICATION

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of such securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


CUSIP No. 22026V105   13G   Page 8 of 8

 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I hereby certify that the information set forth in this statement is true, complete and correct.

Date:    May 24, 2021

 

CLOUGH CAPITAL PARTNERS L.P.
By     Clough Capital Partners LLC,
  its general partner
  By:  

/S/ Charles I. Clough, Jr.

    Charles I. Clough, Jr.,
    managing member
CLOUGH CAPITAL PARTNERS LLC
  By:  

/S/ Charles I. Clough, Jr.

    Charles I. Clough, Jr.,
    managing member
  By:  

/S/ Charles I. Clough, Jr.

    Charles I. Clough, Jr., individually
Get the next $CMPI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CMPI

DatePrice TargetRatingAnalyst
10/6/2021$7.00Neutral → Buy
B of A Securities
More analyst ratings

$CMPI
Press Releases

Fastest customizable press release news feed in the world

See more
  • Axonis Therapeutics Announces $115 Million Series A Financing

    -- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent

    $AKRO
    $APLS
    $AUPH
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Specialty Chemicals
    Consumer Durables
  • venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies

    - venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and closing on approximately $528 million in capital commitments in an oversubscribed fundraise. The firm initiated the fundraise for Fund V in mid-April. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices and funds-of-funds. Under the fund leadership of Managing Partners Richard Gaster, M.D., Ph.D., Corey Goo

    $AKRO
    $APLS
    $AUPH
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Specialty Chemicals
    Consumer Durables
  • Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update

    CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced first quarter 2022 financial results and provided a business update. "We remain focused on the execution of the clinical program for vidutolimod and are delighted with the opportunity to become part of Regeneron, who will help to accelerate the development of vidutolimod as a potential novel treatment for multiple tumor types," said Alan Bash, President and Chief Executive Officer of Checkmate. "This is an excitin

    $CMPI
    Specialty Chemicals
    Consumer Durables

$CMPI
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CMPI
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CMPI
SEC Filings

See more

$CMPI
Leadership Updates

Live Leadership Updates

See more
  • Checkmate Pharmaceuticals Appoints Alan Bash as President and CEO

    CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the appointment of Alan Bash as President and Chief Executive Officer, effective March 1, 2022. Mr. Bash, who will also join the Board of Directors, will succeed Alan Fuhrman, who has served as interim President and Chief Executive Officer since October 2021. Mr. Fuhrman will continue to serve Checkmate as a member of the Board of Directors. "I am very pleased to welcome Alan Bash as President and CEO. With ove

    $CMPI
    Specialty Chemicals
    Consumer Durables
  • Checkmate Pharmaceuticals Strengthens Board of Directors with Appointment of Joy Yan, M.D., Ph.D.

    CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the addition of Joy Yan, M.D., Ph.D. to its Board of Directors ("Board"). "Joy's impressive track record in immuno-oncology focused clinical development will be valuable as we continue to advance vidutolimod toward registration in melanoma and proof of concept in additional indications," commented Alan Fuhrman, Interim CEO and President of Checkmate. "We are pleased to welcome Joy to Checkmate's Board." Dr. Yan

    $CMPI
    Specialty Chemicals
    Consumer Durables
  • Checkmate Pharmaceuticals Announces Key Additions to Executive Management Team

    Robert F. Dolski appointed as Chief Financial Officer Katherine Eade appointed as General Counsel CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the appointment of Robert F. Dolski as Chief Financial Officer. Mr. Dolski brings to Checkmate more than 20 years of diversified management experience as a life sciences financial executive driving the strategy, planning, execution, and financing of private and public biopharmaceutical companies. In addition to Mr

    $CMPI
    Specialty Chemicals
    Consumer Durables

$CMPI
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more